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A number of effects of Pyracetam other that its antihypoxic ef-
fect and influence on memory and process of learning have been dis-
cussed recently. It is known that it stimulates erythropoiesis, 
improves red blood cell deformability (2,6), but it also suppresses 
the "in vitro" platelet activation and aggregation and the release of 
platelets f.4 and beta-thromboglobulin from granules (4,7). 
This study aims at investigating the influence of Pyracetam on 
thrombocytopoiesis in experiments "in vivo" especially as these 
things have not been studied. 
We observed 33 experimental and 35 control female white "Wis-
tar" rats, weighing 170-180 g. The experimental ones were treated for 
3 days, twice a day i.p. with 200 mg/kg of Pyramem (Pharmachim, 
Sofia) disolved in distilled water. The platelets were counted accord-
ing to phase-contrast chamber method (1). Seventy-two hours be-
fore the end of the experiment all the rats were injected with 10jxCi 
Selenomethionine i.p., in order to define the percentage of its in-
corporation in the newly formed platelets (8) - this is an index reflect-
ing the rate of thrombocytopoiesis. The study of megakaryocytes 
(MKC) upon bone marrow smears, coloured after Gimsa's method 
has been done using terms of three-degree scale. The data were ana-
lysed according to variation analysis methods using the t-criterion of 
Student-Fisher. 
Fig. 1 shows that the number of platelets in the rats treated with 
Pyracetam decreases by 17,11 % (p < 0,001) against the control 
group. 
The incorporation of Selenomethionine in the newly formed 
platelets of the experimental and control animals does not differ sub-
stantially. The total number of megakaryocytes in 200 myelok-
aryocytes tends to decrease by 9,02 % in the Pyracetam treated rats. 
The partial megakaryocytogram shows a decrease of almost all forms 
of MKC - especially of the diploid medakaryocytoblasts, basophilic 
and polychromatophilic MKC (in contrast to them oxyphilic MKC tend 
to increase by 28,57 % (fig.2). Our data show that the established 
junctional depressing changes in platelets after treatment with Py-
racetam are accompanied also by a depression of thrombocyto-
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poiesis and megakaryocytopoiesis. Probably, the decreased influx 
of cells from the precursory fund of cells of MKC caused the lower 
number of MKC in the experimental rats. We would explain the de­
crease of platelets in peripheral blood with the possible decreased 
pinching of the latter by grown oxyphilic MKC - this probably causes 
their increase. The thrombopoietin which regulates the pinching of 
the platelets of MKC has been described (3,5). As to the intimate 
mechanism of Pyracetam influence on this cell system - we find it 
difficult to give an answer to this question. These changes in the ac­
tivity of plasma thrombopoietin might lie behind these alterations and 
that will be the aim of our forthcoming investigations. 
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Fig. 1. The data are presented Fig. 2. The data are presented as a 
as mean ± SE per cent deviation to control levels 
accepted as 0. The sign (+) means 
increase but the sign (-) diminution 
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